Hofseth BioCare ASA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021
For the full year, sales was NOK 82.11 million compared to NOK 54.93 million a year ago. Revenue was NOK 87.62 million compared to NOK 69.25 million a year ago. Net loss was NOK 123.9 million compared to NOK 102.09 million a year ago. Basic loss per share from continuing operations was NOK 0.35 compared to NOK 0.31 a year ago. Diluted loss per share from continuing operations was NOK 0.35 compared to NOK 0.31 a year ago.